213 related articles for article (PubMed ID: 30854890)
1. Do tyrosine kinase inhibitors lose favor in treatment of first-line metastatic renal cell carcinoma?
Yaman S; Bilgin B; Şendur MA; Hızal M; Akıncı MB; Yalçın B
Future Oncol; 2019 Mar; 15(9):925-927. PubMed ID: 30854890
[No Abstract] [Full Text] [Related]
2. In brief: Cabozantinib (Cabometyx) for advanced renal cell carcinoma.
Med Lett Drugs Ther; 2016 Jul; 58(1499):e97. PubMed ID: 27403787
[No Abstract] [Full Text] [Related]
3. Influence of Prior Tyrosine Kinase Inhibitor on Survival for Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab or Cabozantinib: Data from a Literature-based Meta-analysis.
Roviello G; Generali D
Eur Urol; 2017 Dec; 72(6):1027-1028. PubMed ID: 28760645
[No Abstract] [Full Text] [Related]
4. Re: E. Jason Abel, Stephen H. Culp, Nizar M. Tannir, et al. Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol 2011;59:10-5.
Ozcan MF; Canda AE; Dizdar O; Altinova S; Akbulut Z; Balbay MD
Eur Urol; 2011 Jun; 59(6):e34. PubMed ID: 21398023
[No Abstract] [Full Text] [Related]
5. Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer.
Di Nunno V; Cimadamore A; Santoni M; Scarpelli M; Fiorentino M; Ciccarese C; Iacovelli R; Cheng L; Lopez-Beltran A; Massari F; Montironi R
Future Oncol; 2018 Oct; 14(25):2559-2564. PubMed ID: 30141348
[No Abstract] [Full Text] [Related]
6. [First-line therapy in advanced renal cell carcinoma : A randomized phase II study to examine early switch of tyrosine kinase inhibitors to nivolumab compared to continued tyrosine kinase inhibitor therapy in patients with advanced or metastatic renal cell carcinoma and stable disease after three months of treatment (NIVOSWITCH)-AN 38/15 of the AUO].
Rexer H; Steiner T; Grünwald V
Urologe A; 2017 Apr; 56(4):509-511. PubMed ID: 28251253
[No Abstract] [Full Text] [Related]
7. Axitinib in metastatic renal cell carcinoma: beyond the second-line setting.
Umeyama Y; Shibasaki Y; Akaza H
Future Oncol; 2017 Sep; 13(21):1839-1852. PubMed ID: 28707479
[TBL] [Abstract][Full Text] [Related]
8. The current status of adjuvant treatment for high-risk renal cell carcinoma.
Hızal M; Şendur MA; Bilgin B; Akıncı MB; Şener Dede D; Yalçın B
Future Oncol; 2017 Oct; 13(23):2017-2020. PubMed ID: 28984480
[No Abstract] [Full Text] [Related]
9. Savolitinib for MET-driven papillary renal cell carcinoma.
Gilbert JA
Lancet Oncol; 2017 Aug; 18(8):e440. PubMed ID: 28669737
[No Abstract] [Full Text] [Related]
10. Treatment patterns and outcomes in patients with unresectable or metastatic renal cell carcinoma in Japan.
Harada K; Nozawa M; Uemura M; Tatsugami K; Osawa T; Yamana K; Kimura G; Fujisawa M; Nonomura N; Eto M; Shinohara N; Tomita Y; Kondo Y; Ochi K; Anazawa Y; Uemura H
Int J Urol; 2019 Feb; 26(2):202-210. PubMed ID: 30345560
[TBL] [Abstract][Full Text] [Related]
11. Cabozantinib improves clinical outcomes in renal cancer.
Das M
Lancet Oncol; 2017 Jan; 18(1):e2. PubMed ID: 27890466
[No Abstract] [Full Text] [Related]
12. Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting.
Procopio G; Derosa L; Gernone A; Morelli F; Sava T; Zustovich F; De Giorgi U; Ferrari V; Sabbatini R; Gasparro D; Felici A; Burattini L; Calvani N; Lo Re G; Banna G; Pia Brizzi M; Rizzo M; Ciuffreda L; Iacovelli R; Ferraù F; Taibi E; Bracarda S; Porta C; Galligioni E; Contu A
Future Oncol; 2014 Aug; 10(10):1741-50. PubMed ID: 24641206
[TBL] [Abstract][Full Text] [Related]
13. Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
Miyake H; Imai S; Harada K; Fujisawa M
Clin Genitourin Cancer; 2016 Feb; 14(1):e19-24. PubMed ID: 26382221
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of the pretreatment aspartate transaminase/alanine transaminase ratio in patients treated with first-line systemic tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma.
Kang M; Yu J; Sung HH; Jeon HG; Jeong BC; Park SH; Jeon SS; Lee HM; Choi HY; Seo SI
Int J Urol; 2018 Jun; 25(6):596-603. PubMed ID: 29756394
[TBL] [Abstract][Full Text] [Related]
15. Changeable Conditional Survival Rates and Associated Prognosticators in Patients with Metastatic Renal Cell Carcinoma Receiving First Line Targeted Therapy.
Kang M; Park JY; Jeong CW; Hwang EC; Song C; Hong SH; Kwak C; Chung J; Sung HH; Jeon HG; Jeong BC; Park SH; Jeon SS; Lee HM; Choi HY; Seo SI
J Urol; 2018 Nov; 200(5):989-995. PubMed ID: 29940249
[TBL] [Abstract][Full Text] [Related]
16. Temsirolimus (Torisel) for advanced renal cell carcinoma.
Med Lett Drugs Ther; 2007 Dec; 49(1276):103-4. PubMed ID: 18084154
[No Abstract] [Full Text] [Related]
17. Early response of C-reactive protein as a predictor of survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.
Yasuda Y; Saito K; Yuasa T; Uehara S; Kawamura N; Yokoyama M; Ishioka J; Matsuoka Y; Yamamoto S; Okuno T; Yonese J; Kihara K; Fujii Y
Int J Clin Oncol; 2017 Dec; 22(6):1081-1086. PubMed ID: 28733795
[TBL] [Abstract][Full Text] [Related]
18. Temsirolimus in the treatment of advanced renal cell carcinoma.
Gore ME
Ann Oncol; 2007 Jul; 18 Suppl 9():ix87-8. PubMed ID: 17631601
[No Abstract] [Full Text] [Related]
19. TOKIO rationale and protocol: a phase II study to evaluate the activity and safety of third-line tyrosine kinase inhibitor after 2 tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma.
Verzoni E; Grassi P; Montone R; Galli G; Necchi A; Procopio G
Tumori; 2015; 101(6):701-3. PubMed ID: 26108242
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of everolimus in patients with advanced renal cell carcinoma refractory or intolerant to VEGFR-TKIs and safety compared with prior VEGFR-TKI treatment.
Kato R; Obara W; Matsuura T; Kato Y; Iwasaki K; Fujioka T
Jpn J Clin Oncol; 2014 May; 44(5):479-85. PubMed ID: 24688083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
